What's Happening

A GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition

A first-time generic indicated for the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILDs

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure

An inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy, and for the treatment of asthma in patients requiring oral corticosteroids

Indicated to increase bone mass in postmenopausal women with osteoporosis at high risk of fracture, in men with osteoporosis at high risk of fracture, in men and women with glucocorticoid-induced osteoporosis with high risk of fracture, in men at high risk of fracture receiving androgen deprivation therapy to nonmetastatic cancer, and in women at high risk of fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

Indicated for the treatment of partial-onset seizures

Indicated for the treatment of partial-onset seizures

An opioid analgesic indicated for the relief of moderate to severe pain

An opioid analgesic indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in patients weighing at least 40 kg

Indicated as a complete regimen for the treatment of HIV-1 infection in patients weighing at least 35 kg as initial therapy in those with no antiretroviral treatment history with HIV-1 RNA less than or equal to 100,000 copies per mL; or to replace a stable antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) for at least six months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Odefsey

Indicated for the treatment of rheumatoid arthritis, giant cell arthritis, cytokine release syndrome, and COVID-19

Indicated for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype (a type of inflammation characterized by high levels of white blood cells) in patients

Indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in obese adults and overweight adults with at least one weight-related comorbidity. This approval is for a new oral tablet formulation of Wegovy, making it the first orally available GLP-1 medication for obesity.

Indicated for the treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis

A biosimilar to Prolia^® (denosumab), this drug is a RANKL inhibitor indicated for the treatment of osteoporosis in postmenopausal women with high risk of fracture, to increase bone mass in men with osteoporosis at a high risk for fracture, for the treatment of glucocorticoid-induced osteoporosis in men and women with high risk of fracture, and more